Autor según el artículo: Verdura, Sara; Cuyas, Elisabet; Ruiz-Torres, Veronica; Micol, Vicente; Joven, Jorge; Bosch-Barrera, Joaquim; Menendez, Javier A.;
Departamento: Medicina i Cirurgia
Autor/es de la URV: Joven Maried, Jorge
Palabras clave: Stat3 Silymarin Silibinin Sencar mouse skin Non-small cell lung cancer Multidrug-resistance Milk thistle Metastasis Lysyl oxidase Histone deacetylase Growth-inhibition Factor-kappa-b Epithelial-mesenchymal transition Emt Drug-resistance Acquired-resistance
Resumen: The flavonolignan silibinin, the major bioactive component of the silymarin extract of Silybum marianum (milk thistle) seeds, is gaining traction as a novel anti-cancer therapeutic. Here, we review the historical developments that have laid the groundwork for the evaluation of silibinin as a chemopreventive and therapeutic agent in human lung cancer, including translational insights into its mechanism of action to control the aggressive behavior of lung carcinoma subtypes prone to metastasis. First, we summarize the evidence from chemically induced primary lung tumors supporting a role for silibinin in lung cancer prevention. Second, we reassess the preclinical and clinical evidence on the effectiveness of silibinin against drug resistance and brain metastasis traits of lung carcinomas. Third, we revisit the transcription factor STAT3 as a central tumor-cell intrinsic and microenvironmental target of silibinin in primary lung tumors and brain metastasis. Finally, by unraveling the selective vulnerability of silibinin-treated tumor cells to drugs using CRISPR-based chemosensitivity screenings (e.g., the hexosamine biosynthesis pathway inhibitor azaserine), we illustrate how the therapeutic use of silibinin against targetable weaknesses might be capitalized in specific lung cancer subtypes (e.g., KRAS/STK11 co-mutant tumors). Forthcoming studies should take up the challenge of developing silibinin and/or next-generation silibinin derivatives as novel lung cancer-preventive and therapeutic biomolecules.
Áreas temáticas: Saúde coletiva Química Pharmacology & pharmacy Pharmaceutical science Molecular medicine Medicina ii Interdisciplinar Farmacia Drug discovery Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Chemistry, medicinal Biotecnología Biodiversidade
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
Direcció de correo del autor: jorge.joven@urv.cat
Identificador del autor: 0000-0003-2749-4541
Fecha de alta del registro: 2024-07-27
Volumen de revista: 14
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://www.mdpi.com/1424-8247/14/6/559
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Pharmaceuticals. 14 (6):
Referencia de l'ítem segons les normes APA: Verdura, Sara; Cuyas, Elisabet; Ruiz-Torres, Veronica; Micol, Vicente; Joven, Jorge; Bosch-Barrera, Joaquim; Menendez, Javier A.; (2021). Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals, 14(6), -. DOI: 10.3390/ph14060559
DOI del artículo: 10.3390/ph14060559
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2021
Tipo de publicación: Journal Publications